Somatic, activating mutations in epidermal growth factor
|
|
- Lionel Montgomery
- 5 years ago
- Views:
Transcription
1 Brief Report Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort Helena A. Yu, MD,* Maria E. Arcila, MD, Megan Harlan Fleischut, MS, Zsofia Stadler, MD, Marc Ladanyi, MD, Michael F. Berger, PhD, Mark Robson, MD, and Gregory J. Riely, MD, PhD* Abstract: Activating mutations in epidermal growth factor receptor (EGFR) are present in a subset of lung cancers, and predict sensitivity to EGFR tyrosine kinase inhibitors. Acquisition of EGFR T790M is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors and rarely is seen before treatment. Germline EGFR T790M mutations have been reported, although the penetrance and clinical significance of this mutation is unknown. We describe the identification of a patient with an EGFR T790M germline mutation and subsequent germline testing in her unaffected family members. Genetic testing revealed two additional EGFR T790M germline carriers, one of which was subsequently diagnosed with metastatic lung adenocarcinoma. (J Thorac Oncol. 2014;9: ) Somatic, activating mutations in epidermal growth factor receptor (EGFR; Exon 19 deletions, as well as point mutations in L858R, G719, L861) promote oncogenesis in a specific subset of lung adenocarcinomas. 1 In patients with EGFR mutant lung cancer, EGFR tyrosine kinase inhibitors (TKIs) are more effective than cytotoxic chemotherapy although patients develop resistance after a median of 12 to 16 months on therapy. 2 The most common mechanism of resistance to EGFR TKIs is the acquisition of the EGFR T790M point mutation, which occurs in 60% of patients. 3,4 De novo EGFR T790M mutations are rarely seen by standard genotyping methods, and occur in less than 1% of all lung cancers and approximately 2% of all EGFR mutant lung cancers. 5 *Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine; Department of Pathology, Clinical Genetics Service, Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and Weill Cornell Medical College, New York, New York. Disclosure: Gregory Riely has consulted for Ariad, Abbott Molecular, Foundation Medicine and Celgene, and has received research support from Infinity Pharmaceuticals, Bristol-Myers Squibb, Novartis, Chugai, Pfizer, Millennium, and GlaxoSmithKline. Marc Ladanyi has consulted for Novartis and NanoString. The other authors declare no conflict of interest. Address correspondence to: Helena A. Yu, MD, Memorial Sloan-Kettering Cancer Center, 300 East 66th St., New York, NY yuh@ mskcc.org Copyright 2014 by the International Association for the Study of Lung Cancer ISSN: /14/ Germline EGFR T790M mutations have been reported in association with familial non small-cell lung cancer although the degree of risk, penetrance, and the resultant clinical syndrome has not been fully elucidated. 6 Here we describe the results of comprehensive molecular testing on multiple synchronous lung tumors in a patient who had genetic testing revealing a germline EGFR T790M mutation. The identification of the germline mutation in the proband led to cohort testing of her unaffected relatives, resulting in the discovery of two additional EGFR T790M germline carriers, one of whom was subsequently diagnosed with metastatic lung adenocarcinoma. The index case is a 44-year-old never-smoker with no family history of lung cancer, who initially presented with enlarged axillary lymph nodes. Imaging revealed multiple bilateral ground-glass opacities within the lungs. She underwent right-sided wedge biopsies, and biopsies of the right middle lobe and right lower lobe revealed well-differentiated adenocarcinoma. The right middle lobe nodule harbored both an EGFR T790M mutation and a 15bp EGFR exon 19 deletion. She underwent a left-sided thoracotomy with multiple wedge biopsies of the left lower and left upper lobes to further define the extent of her disease. Four discrete left lower lobe (LLL) nodules and one left upper lobe (LUL) nodule were excised and were consistent with structurally distinct adenocarcinomas, indicating synchronous primary lung cancers rather than metastatic disease (Fig. 1). The EGFR T790M mutation was identified in all samples upon routine diagnostic molecular testing. Four samples (3 from the LLL, 1 from the LUL) harbored an EGFR L858R point mutation. One sample from the LLL had a 3bp deletion in EGFR exon 19 found using fragment analysis and confirmed by Sanger sequencing (Table 1). Because of a strong family history of cancer (Table 2) and her new diagnosis of multiple primary lung cancers, she was referred to clinical genetics for evaluation for a germline susceptibility to cancer. She had testing performed on peripheral blood for both EGFR*2369C to T (T790M) and BRCA1/2 because of her family history of breast and ovarian cancer. She tested positive for the germline EGFR T790M mutation, and was also found to have a BRCA 2 variation of uncertain significance at L459S (1604 T to C). She is followed regularly with interval computed tomography scans that indicate stable bilateral pulmonary nodules and ground-glass opacities (Fig. 2, Patient A). She continues to be monitored expectantly on no systemic therapy. 554 Journal of Thoracic Oncology Volume 9, Number 4, April 2014
2 Journal of Thoracic Oncology Volume 9, Number 4, April 2014 Germline EGFR T790M Mutation in Familial Cohort FIGURE 1. Hematoxylin and eosin stained sections of six tumors at intermediate magnification show adenocarcinomas of mixed phenotype with varying proportions of lepidic, bronchoalveolar, acinar, and papillary patterns. All tumors appeared structurally distinct, favoring separate primaries. Further molecular analysis of this patient s synchronous tumors was performed to gain insight on the molecular progression from a germline susceptibility mutation, EGFR T790M, to clinically evident malignancy. Massively parallel sequencing 7 was performed of all exons of 230 cancer genes (see Supplementary Data for gene list, Supplemental Digital Content 1, The technique used to sequence exons of genes of interest 7 and the technical implementation of an oncogene screening profile 8 have been described previously. Exonic DNA was captured via solutionbased hybrid selection 9 and sequenced on the Illumina HiSeq platform (Illumina, San Diego, CA). The sequencing data were analyzed for base mutations, insertions, deletions, copy number alterations, and genomic rearrangements in all target genes. TABLE 1. Synchronous Tumors and Resultant Diagnostic Molecular Testing Tumor Standard Molecular Path NGS Mutation Profile T-1 (RML) EGFR T790M, 15bp exon 19 del T-2 (RUL) EGFR T790M EGFR T790M, ARID1A K1938N T-3 (LLL) EGFR T790M, L858R EGFR T790M, L858R T-4 (LLL) EGFR T790M, L858R EGFR T790M, L858R T-5 (LLL) EGFR T790M, L858R T-6 (LLL) EGFR T790M, 3bp exon 19 del T-7 (LUL) EGFR T790M, L858R A peripheral blood sample and three tumor samples (T-2, T-3, T-4) yielded adequate DNA for analysis on this platform. The EGFR T790M variant was detected in all three tumor samples (T-2, T-3, T-4) and the normal blood at allele frequencies of 48%, 51%, 48%, and 52%, respectively, as expected for a germline variant. The BRCA2 L459S germline variant was identified in the peripheral blood normal tissue in 413 of 868 reads. T-2 had an additional ARID1A K1938N somatic point mutation at an allele frequency of 19%, T-3 and T-4 had EGFR L858R somatic point mutations at allele frequencies of 11% and 16%, respectively. No additional insertions, deletions, point mutations or rearrangements were identified in the 230 cancer genes analyzed (Fig. 3). After our proband was identified as a carrier of a germline EGFR T790M mutation, her mother was referred to clinical genetics for germline EGFR T790M testing to ascertain whether the mutation in the proband was a de novo event or an inherited EGFR 2369C>T (T790M) germline mutation. After the initial clinical genetics evaluation, the proband s mother was diagnosed with metastatic lung adenocarcinoma presenting with bilateral ground-glass opacities and pulmonary nodules similar to the proband. She returned to clinical genetics and was informed of her positive EGFR 2369C>T (T790M) germline mutation. BRCA 2 testing for the variation of uncertain significance at L459S was not performed because of lack of insurance coverage for the requested test. Because of the T790M germline mutation found in two family members, we offered all interested family members genetic counseling and germline testing. Eleven family TABLE 2. Family History of Proband Family Member Breast Ovarian Cancer Pancreatic Cancer Prostate Cancer Leukemia Father Maternal aunt #1 (premenopausal) Maternal aunt #2 (premenopausal) Maternal aunt #3 (postmenopausal) Maternal aunt #4 Maternal cousin (premenopausal) Maternal grandfather Copyright 2014 by the International Association for the Study of Lung Cancer 555
3 Yu et al. Journal of Thoracic Oncology Volume 9, Number 4, April 2014 FIGURE 2. Serial interval computed tomography scans of patients with germline epidermal growth factor receptor T790M. members (Fig. 4) came to an informational session where voluntary germline testing was offered. Testing was performed on seven family members. Of the seven people tested, the proband s daughter was the only one found to carry the EGFR 2369C>T (T790M) germline mutation (Table 3). Germline EGFR T790M mutation carriers need to be prospectively studied to better understand the clinical implications of this germline mutation. In mouse models, the presence of the EGFR T790M mutation induces tumor formation, suggesting that the mutation is sufficient for oncogenesis. 10 Clinically, the presence of germline EGFR T790M is associated with the development of lung adenocarcinoma, although the penetrance and clinical significance of FIGURE 3. The results from next generation sequencing on tumor 2 (T-2), tumor 3 (T-3), tumor 4 (T-4), and normal blood. The EGFR T790M point mutation was identified in all samples. In addition to EGFR T790M, T-2 had evidence of an ARID1A K1938N mutation, and T-3 and T-4 had evidence of an EGFR L858R point mutation. EGFR, epidermal growth factor receptor. 556 Copyright 2014 by the International Association for the Study of Lung Cancer
4 Journal of Thoracic Oncology Volume 9, Number 4, April 2014 Germline EGFR T790M Mutation in Familial Cohort FIGURE 4. Pedigree with labeled family members and germline testing results. this mutation is not fully elucidated. Screening for germline T790M mutations in unselected populations has not been fruitful. 11,12 However, germline EGFR T790M mutations are present in approximately 50% of all patients with baseline EGFR T790M identified in their pretreatment tumor specimens. 13 We have recommended that all patients with baseline EGFR T790M identified in their lung tumor tissue be referred to clinical genetics to discuss EGFR T790M germline testing. 13 In our practice, patients with germline EGFR T790M mutations can present radiographically with bilateral groundglass opacities and pulmonary nodules (Fig. 2), and often have an indolent disease course. Two of our four patients with confirmed germline EGFR T790M are being monitored expectantly and have gone as long as six years off treatment with stable disease. This is consistent with cell line data that EGFRmutant cell lines that acquire EGFR T790M mutation display indolent growth. 14 However, this is not uniformly so, as the TABLE 3. Germline Testing Results Location on Pedigree Relationship to Proband Tested (Result) 1 Mother Yes (positive) 2 Daughter Yes (positive) 3 Sister Yes (negative) 4 Brother Yes (negative) 5 Niece Yes (negative) 6 Maternal uncle Yes (negative) 7 First cousin Yes (negative) 8 First cousin Yes (negative) 9 First cousin No 10 First cousin No Not pictured Second cousin No Not pictured Third cousin No other two patients had more aggressive, widely metastatic disease treated with chemotherapy and both eventually died from their disease. All four patients with germline EGFR T790M were never-smokers, and information regarding response to erlotinib in germline EGFR T790M carriers is not available as none were treated with erlotinib monotherapy. Molecular testing of our patient revealed few concurrent somatic mutations. Besides the EGFR exon 19 deletion identified in one lesion, concurrent EGFR L858R and EGFR T790M mutations were identified in two of the samples, which has been previously described. 6 Another sample had a concurrent ARID1A mutation, which was recently reported in lung adenocarcinoma and is known to be oncogenic in other malignancies. 15 Newer TKIs, such as AP26113 and CO-1686, have selectivity for EGFR T790M over wild-type EGFR and are currently in early-phase studies (NCT and NCT , respectively). Chemoprevention using an EGFR T790M selective agent could be studied in unaffected T790M germline carriers, similar to the use of tamoxifen in the breast cancer high-risk population. In addition, screening computed tomography scans for patients with germline EGFR T790M mutations may be warranted as is recommended for other high-risk populations. The highest incidence of germline EGFR T790M mutations have been identified in patients with pretreatment somatic EGFR T790M mutations, and continued referral of these patients to clinical genetics is important to discuss germline testing. Carriers of EGFR T790M need to be followed prospectively to learn the clinical significance of this germline mutation. Other somatic mutations (EGFR L858R, EGFR exon 19 deletions, ARID1A K1938N) occur concurrently with EGFR T790M, and analysis of these germline carriers may provide insight into the oncogenic process from germline mutation carrier to clinically evident malignancy. The ultimate goal of this line of research is to understand the cancer risk associated with this germline mutation, identify Copyright 2014 by the International Association for the Study of Lung Cancer 557
5 Yu et al. Journal of Thoracic Oncology Volume 9, Number 4, April 2014 carriers, and provide them with interventions that will reduce their risk of cancer-related mortality. REFERENCES 1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13: Pao W MV, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2: Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19: Riely G, Yu H, Arcila M, et al. Response to Erlotinib and Prognosis in Patients with De Novo Epidermal Growth Factor Receptor T790M Mutations. J Clin Oncol 2013:31 (suppl; abstr 8018). 6. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37: Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11: Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29: Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009;27: Regales L, Balak MN, Gong Y, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007;2:e Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007;67: Girard N, Lou E, Azzoli CG, et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010;16: Oxnard GR, Miller VA, Robson ME, et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012;7: Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFRmutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150: Copyright 2014 by the International Association for the Study of Lung Cancer
Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationExon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Case Report Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Yu-Ting Wang, Wei-Wei Ning, Jing Li, Jian-n Huang Department of Respiratory Medicine, the First ffiliated
More informationOriginal Article. Cancer January 1,
Twice Weekly Pulse and Daily Continuous-Dose Erlotinib as Initial Treatment for Patients With Epidermal Growth Factor Receptor Mutant Lung Cancers and Brain Metastases Kathryn C. Arbour, MD 1 ; Mark G.
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationThe discovery of targetable driver mutations in a subset of
Original Article Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers Anya M. Litvak, MD,* Paul K. Paik, MD,* Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD,*
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/3/75/75ra26/dc1 Supplementary Materials for Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia V. Sequist,*
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationLung cancer is ranked as the most common cause of cancer
BRIEF REPORT Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors Susumu Kobayashi, MD, PhD, Hannah M. Canepa, BA, Alexandra S. Bailey, MD, Sohei Nakayama, MD, PhD, Norihiro Yamaguchi,
More informationLung cancer represents the leading cause of death from
ORIGINAL ARTICLE Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations Kenichi Nishie, MD,*
More informationCHAPTER 8A. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well
CHAPTER 8A High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well J.L. Kuiper, E.F. Smit Lung Cancer 2013 Apr;80(1):102-5 Chapter
More informationOsimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Editorial : a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma Niki Karachaliou 1, Feliciano Barron Barron 2, Santiago Viteri 3, Miguel Angel Molina 4, Rafael
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationRead, Interpret, and Communicate Test Results
Read, Interpret, and Communicate Test Results Effective interpretation of epidermal growth factor receptor (EGFR) T790M mutation test results at progression will help physicians to set patient expectations
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationABSTRACT. PERMANYER. J Cancerol. 2015;2:56-63
www.journalofcancerology.com PERMANYER J Cancerol. 2015;2:56-63 JOURNAL OF CANCEROLOGY REVIEW ARTICLE Outcome of Patients with Lung Adenocarcinoma Harboring Common and Rare Epidermal Growth Factor Receptor
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationNIH Public Access Author Manuscript Clin Cancer Res. Author manuscript; available in PMC 2014 April 15.
NIH Public Access Author Manuscript Published in final edited form as: Clin Cancer Res. 2013 April 15; 19(8): 2240 2247. doi:10.1158/1078-0432.ccr-12-2246. Analysis of Tumor Specimens at the Time of Acquired
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationLung cancer is the most common cause of cancer death in
ORIGINAL ARTICLE Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? Catherine
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationAdenocarcinoma of the lung is the leading cause of cancerrelated
ORIGINAL ARTICLE Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, MD,* Stephen Broderick, MD, Qin Zhou, MA, Dhananjay Chitale, MD, Allan
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationMP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationCASE REPORT. Abstract. Introduction. Case Report
SE REPORT n utopsy ase of Two Distinct, cquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung denocarcinoma: Small ell arcinoma Transformation and Epidermal Growth Factor Receptor
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationANTICANCER RESEARCH 26: (2006)
Diffuse Micronodular Pulmonary Metastasis of Lung Adenocarcinoma Predicts Gefitinib Response in Association with Epidermal Growth Factor Receptor Mutations MAKOTO KOBAYASHI 1, TAMOTSU TAKEUCHI 2, KENTARO
More informationBRCA Precertification Information Request Form
BRCA Precertification Information Request Form Failure to complete this form in its entirety may result in the delay of review. Fax to: BRCA Precertification Department Fax number: 1-860-975-9126 Section
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationThe estimation of tumor cell percentage for molecular testing by pathologists is not accurate
168 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The estimation of tumor cell percentage for molecular testing by pathologists is not accurate Alexander JJ Smits 1,2, J Alain Kummer 1, Peter
More informationLung cancer is the leading cause of cancer deaths worldwide.
Original Article Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI Akito Hata, MD,* Nobuyuki Katakami, MD, PhD,*
More informationZan-Feng Wang 1*, Sheng-Xiang Ren 2, Wei Li 2 and Guang-Hui Gao 2
Wang et al. BMC Cancer (2018) 18:148 https://doi.org/10.1186/s12885-018-4075-5 RESEARCH ARTICLE Open Access Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationRepeated Favorable Responses to Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
http://dx.doi.org/10.4046/trd.2013.74.3.129 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:129-133 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationApproach to biomarker testing: perspectives from various specialties
ORIGINAL ARTICLE Approach to biomarker testing: perspectives from various specialties M.R. Sung bsc,* P.M. Ellis md, S. Verma md, E. Duncan, and N.B. Leighl md mmsc* ABSTRACT Background Despite its importance
More informationBreast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center
Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationA Patient s Guide to. Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer.
More informationAdjuvant Therapies for Lung Cancers: New Directions
Adjuvant Therapies for Lung Cancers: New Directions Mark G Kris, MD Member and Attending Physician William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Professor of Medicine, Weill
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationSomatic mutations in the epidermal growth factor
Neuro-Oncology 13(12):1364 1369, 2011. doi:10.1093/neuonc/nor121 Advance Access publication August 24, 2011 NEURO-ONCOLOGY Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small
More informationSomatic mutations in the epidermal growth factor
Neuro-Oncology 13(12):1364 1369, 2011. doi:10.1093/neuonc/nor121 Advance Access publication August 24, 2011 NEURO-ONCOLOGY Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationYan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract
Original Article Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations Yan Zhang
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jacobsen E, Shanmugam V, Jagannathan J. Rosai Dorfman disease
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationGTS. Earn CME credits at
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center Sandra P. D Angelo, MD, Bernard Park,
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationProactive Patient Paves the Way for Genetic Testing of Eight Family Members
CASE STUDY Proactive Patient Paves the Way for Genetic Testing of Eight Family Members Quick Summary Samar Mohite * was diagnosed with colon adenocarcinoma at the age of 49 years. Genetic counselling was
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationNext-generation sequencing based clinical testing for lung cancer in Japan
Review Article Next-generation sequencing based clinical testing for lung cancer in Japan Masayuki Takeda 1, Kazuko Sakai 2, Kazuhiko Nakagawa 1, Kazuto Nishio 2 1 Department of Medical Oncology, 2 Department
More informationCase Presentation. Case, continued. Case, continued. Case, continued. Lung Cancer in 2014: The New Paradigm
Lung Cancer in 2014: The New Paradigm James J. Stark, MD, FACP Professor of Clinical Internal Medicine Eastern Virginia Medical School August 20, 2014 Case Presentation 62 year old man, former smoker,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationLung cancer is the leading cause of cancer related death
Original Article Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non Small-Cell Lung Cancer Jih-Hsiang Lee, MD,* Yu-Lin Lin, MD,* Wei-Hsun Hsu, MD,* Hsuan-Yu Chen, PhD, # Yeun-Chung
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationJ Clin Oncol 30: by American Society of Clinical Oncology INTRODUCTION
VOLUME 30 NUMBER 4 FEBRUARY 1 12 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pretreatment Epidermal Growth Factor Receptor (EGFR) Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationDiagnostic with alternative sample types (liquid biopsy)
MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationThe treatment of advanced non small-cell lung cancer
Brief Report PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non Small-Cell Lung Cancer Denis Soulières, MD,* Fred R. Hirsch, MD, PhD, Frances A. Shepherd,
More informationEGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE EGFR s in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Can Pi 1,2*, Chong-Rui Xu 2*, Ming-feng Zhang
More information